These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 19154451)

  • 1. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
    Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
    BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kumano M; Miyake H; Muramaki M; Furukawa J; Takenaka A; Fujisawa M
    Urol Oncol; 2009; 27(2):180-6. PubMed ID: 18439850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.
    Allgayer H; Heiss MM; Riesenberg R; Grützner KU; Tarabichi A; Babic R; Schildberg FW
    Cancer Res; 1997 Apr; 57(7):1394-9. PubMed ID: 9102229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
    Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
    Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
    Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
    J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
    Zhou Q; Liang LJ; Peng BG; Zhen YY
    Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
    Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
    BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
    Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
    Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
    Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
    BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
    Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
    J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
    Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
    Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases.
    Schoppmeyer K; Frühauf N; Oldhafer K; Seeber S; Kasimir-Bauer S
    Oncol Rep; 2006 Feb; 15(2):449-54. PubMed ID: 16391868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer.
    Wimberger P; Heubner M; Otterbach F; Fehm T; Kimmig R; Kasimir-Bauer S
    Gynecol Oncol; 2007 Nov; 107(2):331-8. PubMed ID: 17764727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
    Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
    Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
    Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
    Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer.
    Pfitzenmaier J; Ellis WJ; Hawley S; Arfman EW; Klein JR; Lange PH; Vessella RL
    Urol Oncol; 2007; 25(3):214-20. PubMed ID: 17483018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.
    Peyromaure M; Camparo P; Badoual C; Descazeaud A; Dinh-Xuan AT
    BJU Int; 2007 May; 99(5):1150-3. PubMed ID: 17437444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
    Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
    BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.